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Abstract. Background/Aim: The aim of this study was to
analyze the patterns of treatment and outcomes in patients with
a large number of brain metastases, arbitrarily defined as 20
or more lesions. These patients are typically excluded from
studies of focal brain treatment, e.g., surgery or radiosurgery,
and might have a limited prognosis. Patients and Methods: This
was a retrospective single-institution analysis. Overall, 11
patients were identified from a prospectively maintained
database. Results: Ten patients had received active treatment (9
whole-brain radiotherapy, 7 systemic therapy). Median survival
was 5.0 months without long-term survival beyond 13 months.
Patients with better performance status had numerically longer
survival, however we did not identify baseline parameters with
a significant impact on survival. Conclusion: While long-term
survival was not observed in this small study, most patients
survived long enough to experience symptomatic improvement
from whole-brain radiotherapy. Therefore, we recommend
multidisciplinary assessment of the patients’ prognosis and
systemic treatment options, and initiation of whole-brain
radiotherapy if survival is not limited to 1-2 months.  
Advances in diagnostic imaging have facilitated detection of
small intracranial lesions (1-3) and thus resulted in decreasing
numbers of patients who present with 1-3 brain metastases
from solid extracranial primary tumors, e.g., lung, breast,
kidney cancer or malignant melanoma (4). Many patients with
1-3 brain metastases are considered adequate candidates for
surgery and/or radiosurgery (SRS) (5-8). Technically, it is also
feasible to irradiate more than three lesions with SRS,
however there is no consensus about the maximum number of
metastases that qualify for focal treatment, as opposed to
whole-brain radiotherapy (WBRT) (9). Some groups have
offered SRS to selected patients with 4-10 brain metastases,
others also to those with even more lesions (10-13). With
increasing lesion number, durable brain control is difficult to
achieve. There is scarce data about the group of patients with
a large number of brain metastases, and therefore we analyzed
our Institution’s prospectively maintained database. We
arbitrarily decided to focus on patients with 20 or more brain
metastases, a group which typically is excluded from studies
of SRS or other focal treatments.  
Materials and Methods
Patients and treatment. A retrospective study of patients with 20 or
more synchronous or metachronous parenchymal brain metastases
from histologically verified extracranial primary tumors treated at our
hospital was performed. Treatment was individualized and consisted
of WBRT, combined WBRT with systemic therapy or best supportive
care (BSC). Systemic treatment was usually prescribed as judged
appropriate by the patients’ medical oncologists. The patients were
treated between January 01, 2007 and December 31, 2017 and
identified from a previously described database (14, 15). Brain
magnetic resonance imaging was performed to assess the number of
intracranial metastases and to exclude leptomeningeal disease. 
Statistical methods. Overall survival (time to death) from the first
day of radiotherapy or, in case of BSC, from imaging diagnosis was
calculated employing the Kaplan–Meier method, and different
groups were compared using the log-rank test (SPSS 24, IBM Corp.,
Armonk, NY, USA). Date of death was known in all patients.
Statistical significance was defined as p<0.05 throughout this study
in two-sided tests. 
Results
Patient characteristics. Overall, 11 patients were identified
from the database, corresponding to less than 5% of patients.
Four patients had primary malignant melanoma and small
cell lung cancer (SCLC), respectively. Non-small cell lung
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cancer (NSCLC) was present in 2 patients, while one had a
diagnosis of breast cancer. Only one patient had brain-only
dissemination and two had Karnofsky performance status
(KPS) >70. Further patient characteristics are shown in Table
I, while imaging findings are displayed in Figure 1. 
Treatment. Ten patients received active treatment, and one who
initially was referred to WBRT was converted to BSC due to
rapid deterioration of his KPS. Overall, nine patients received
WBRT, commonly 10 fractions of 3 Gy. Seven patients received
systemic therapy after their brain metastases diagnosis. 
Survival. Median overall survival of all 11 patients was 5.0
months (range=1.2-12.6 months). In the absence of systemic
treatment, median survival was 2.0 months. If KPS was 70 or
better, median survival was 8.3 months compared to 3.5
months if KPS was <70 (p=0.78). Age, size of the largest
lesion, time interval between primary diagnosis and brain
metastases, and other baseline variables were not significantly
associated with survival either.  
Discussion
We performed a retrospective study of patients with brain
metastases and presumably limited prognosis due to the fact
that the presence of many lesions rendered these patients
ineligible for surgery or SRS, at least according to our
institution’s policy. SRS has recently gained increasing
acceptance also in patients with more than just 1-2 brain
metastases, because the probability of local lesion control is
much higher after SRS than after WBRT, simply as a
function of the higher ablative radiation dose delivered. In
contrast, development of distant brain failure often results in
need for further SRS or WBRT (9, 10). Besides local brain
control, a variety of other factors that can be combined in
prognostic scores are crucial determinants of long-term
survival (5, 6, 8, 16, 17).  
Recent studies of SRS reported median numbers of
metastases of 2 (range=1-17 metastases) (12) and 5
(range=4-23 metastases) (11), reflecting the different
approaches chosen in different institutions. The latter study
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Table I. Patient characteristics. 
Diagnosis            Time     Primary   Extracranial Neurologic Response   Treatment       Systemic    KPS Diameter Number  Age Survival       Cause 
                          interval     tumor       metastases    symptoms        to                                   therapy               of largest      of          in          in                 of
                               in       controlled                                              steroids                                                             lesion     lesions   years  months          death
                          months                                                                                                                                            in cm                                                          
HER2+                 10            Yes          Hep, oss            Yes            Yes           WBRT      Trastuzumab   70        1.9            50         50       10.2     Impossible to 
breast cancer                                                                                                       30 Gy                                                                                                     determine
Adeno                    0              No               Hep               Yes             No      1 cycle CTx,         No            70        2.6            20         72        1.5            Likely 
NSCLC                                                                                                          died before                                                                                                neurologic
                                                                                                                             WBRT
Melanoma            156           Yes          Pul, lym            Yes             No           WBRT      Dabrafenib +  70        3.2            24         49        8.3        Neurologic
                                                                                                                              30 Gy         Trametinib
Melanoma             33            Yes          Pul, adr,           Yes             No           WBRT              No            60        3.0            21         67        2.0            Likely 
                                                                    oth                                                     30 Gy                                                                                                     neurologic
Adeno                    0             Yes          Hep, oss            No             NA           WBRT             CTx          60        1.1            50         69       12.6       Likely non-
NSCLC                                                                                                               30 Gy                                                                                                     neurologic
SCLC                     0              No                No                 No             NA     4 cycles CTx,       CTx          90        1.8            20         67       10.5       Likely non-
                                                                                                                         then WBRT                                                                                               neurologic
                                                                                                                              30 Gy
Melanoma             28            Yes          Hep, pul,          Yes            Yes           WBRT             CTx          80        3.6            25         40        2.3      Impossible to 
                                                                    oss                                                40 Gy with                                                                                                 determine
                                                                                                                            temozo-
                                                                                                                             lomide
SCLC                     6             Yes          Hep, oss            Yes               ?             WBRT              No            60        1.0            36         72        5.0        Likely non-
                                                                                                                              30 Gy                                                                                                     neurologic
Melanoma            120            No           Pul, adr,           Yes            Yes           WBRT             CTx          60        3.0            23         64        5.5      Impossible to 
                                                                    oth                                                     36 Gy                                                                                                     determine
SCLC                     6             Yes          Hep, adr,          Yes             No           WBRT              No            30        1.3            50         51        2.0             Non-
                                                                    oss                                                     30 Gy                                                                                                     neurologic
SCLC                     4              No          Hep, adr,          Yes            Yes        Converted           No            60        1.5            25         75        1.2        Likely non-
                                                                    oth                                                    to BSC                                                                                                    neurologic
NSCLC: Non-small cell lung cancer; SCLC: small cell lung cancer; hep: hepatic; oss: osseous; pul: pulmonary; lym: lymph nodes; adr: adrenal gland;
oth: others; NA: not applicable; CTx: chemotherapy; WBRT: whole-brain radiotherapy; BSC: best supportive care; KPS: Karnofsky performance status.
of patients with at least four metastases reported better
survival with smaller total tumor volume (11). Ali et al. (13)
analysed more than 5,000 patients. The maximum number of
metastases was not reported. The median survival of patients
with >10 brain metastases was lower than that of those with
2-10 lesions (6.3 months vs. 5.5 months, p=0.025). When
lesion number was modelled as a continuous variable rather
than using the cut-off, they observed a step-wise 4% increase
in the hazard of death for every increment of 6-7 brain
metastases (p<0.001). In our study, median survival was 5.0
months and none of the patients had ever received SRS.
Overall 5 patients survived for less than 3 months,
emphasizing that careful selection is needed. Poor KPS and
ineligibility for systemic therapy should be taken into
consideration when deciding about WBRT. Since almost all
patients had extracranial metastases, long-term survival is
not purely a function of optimal local control in the brain.
None of our patients had miliary brain metastases from
EGFR mutated NSCLC, a special entity that may respond to
targeted systemic therapy (18). 
Chang et al. evaluated 323 patients who underwent SRS
for metastatic brain lesions (19). Patients were divided into
4 groups according to the number of lesions visible on
magnetic resonance (MR) images: Group 1, 1-5 lesions;
Group 2, 6-10 lesions: Group 3, 11-15 lesions; and Group 4,
>15 lesions. The overall median survival time after SRS was
10 months. The median survival time of each group was as
follows: Group 1, 10 months; Group 2, 10 months; Group 3,
13 months; and Group 4, 8 months. There was no statistical
difference between survival times after SRS (p=0.554),
although the probability of development of new lesions in
the brain was greater in Group 4 (p=0.014). Inter-study
comparison of the survival outcomes is difficult, because
Asian populations often include larger proportions of
NSCLC patients with actionable mutations and also because
patients managed with BSC were not included. 
Limitations of the present study include the limited
number of patients, statistical power of subgroup analyses,
and its retrospective design. In many cases we were unable
to firmly establish neurologic vs. other causes of death.
Furthermore, quality of life data confirming the clinical
benefit of WBRT and its potential neurocognitive impact
were not available. A currently recruiting study is expected
to provide relevant data in this context (20). CAR-Study B
is a prospective randomized trial comparing cognitive
outcome after SRS or WBRT in patients with 11-20 newly
diagnosed brain metastases on a contrast-enhanced MRI
scan, KPS ≥70 and life expectancy of at least 3 months.
Secondary endpoints include overall survival, local control,
development of new brain metastases, cognitive functioning
over time, quality of life, depression, anxiety and fatigue.
Assessments are scheduled at baseline and at 3, 6, 9, 12 and
15 months after treatment.
Conclusion
While long-term survival was not observed in this small
study, most patients survived long enough to experience
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Figure 1. Magnetic resonance imaging scans of two study patients who presented with multiple contrast-enhancing brain metastases (examples of
infra- (patient 7) and supratentorial (patient 5) disease extent, respectively).
symptomatic improvement from WBRT. Therefore, we
recommend multidisciplinary assessment of the patients’
prognosis and systemic treatment options, and initiation of
WBRT if survival is not limited to 1-2 months.  
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